NCT06785818View on ClinicalTrials.gov

Long-term Follow up Local Registry Study of Kymriah in South Korea

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

March 12, 2025

Primary Completion Date

December 30, 2039

Study Completion Date

December 30, 2039

Conditions
B-Cell Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Interventions
OTHER

Tisagenlecleucel

This is an observational study. There is no treatment allocation. The decision to initiate tisagenlecleucel will be based solely on clinical judgement.

Trial Locations (8)

13620

RECRUITING

Novartis Investigative Site, Bundang Gu

49201

RECRUITING

Novartis Investigative Site, Busan

405 760

RECRUITING

Novartis Investigative Site, Incheon

03080

RECRUITING

Novartis Investigative Site, Seoul

04401

RECRUITING

Novartis Investigative Site, Seoul

05505

RECRUITING

Novartis Investigative Site, Seoul

06351

RECRUITING

Novartis Investigative Site, Seoul

06591

RECRUITING

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY